21 recruiting, 12 not yet recruiting, 2 active not recruiting, 2 withdrawn. 13 Phase 1, 13 Phase 2, 4 Not applicable, 4 Phase 4, 2 Early Phase 1.
Follow Lupus Nephritis (LN): new trials by email Literature Review of Lupus Nephritis (LN) trials Research Report on Lupus Nephritis (LN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lupus Nephritis Care Pathway Lupus Nephritis (LN) Care Pathway - Lupus Nephritis (LN) | Not applicable | Recruiting | Duke University | 25 | 2026-10-14 | 2026-10-19 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy C-CAR168 - Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE) | Phase 2 | Not yet recruiting | AbelZeta Inc. | 50 | 2026-09-30 | 2026-10-13 |
| Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis TranspoCART19 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 10 | 2026-09-23 | 2026-10-01 |
| Safety and Efficacy of ONT01 in Lupus ONT01 is a small molecule CD11b modulator. - Lupus Nephritis (LN), Lupus Nephritis - WHO Class III | Early Phase 1 | Recruiting | Hospital for Special Surgery, New York | 61 | 2026-09-04 | 2025-11-20 |
| Neutrophil Extracellular Traps and Lupus Nephritis Serum Neutrophil Extracellular Traps - Lupus Nephritis (LN) | Not yet recruiting | Assiut University | 100 | 2026-09-01 | 2026-07-23 | |
| A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | iCell Gene Therapeutics | 20 | 2026-09-01 | 2026-09-17 |
| Predictors of ICU Admission and In-Hospital Mortality in Hospitalized Patients With Lupus Nephritis: The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and C Reactive Protein to Serum Albumin Ratio Lupus Nephritis (LN) | Not yet recruiting | Khaled Samir Malak Nashed | 55 | 2026-09-01 | 2026-08-26 | |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial) High-dose prednisone, Low-dose prednisone - Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN) | Phase 4 | Recruiting | Peking Union Medical College Hospital | 198 | 2026-07-01 | 2026-07-22 |
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Not yet recruiting | Assiut University | 156 | 2026-07-01 | 2026-07-22 | |
| A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases MTM-H-001 Injection - Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Not applicable | Not yet recruiting | Beijing GoBroad Hospital | 75 | 2026-06-01 | 2026-05-18 |
| The Role of Transforming Growth Factor- Beta (TGF- β) Expression in Renal Biopsy of Lupus Nephritis Patients renal biopsy - Lupus Nephritis (LN) | Not applicable | Active not recruiting | Ain Shams University | 30 | 2026-05-31 | 2026-09-16 |
| Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification - Lupus Nephritis (LN), Chronic Kidney Disease | Phase 1 / Phase 2 | Active not recruiting | Hospital Civil Juan I. Menchaca | 30 | 2026-05-28 | 2026-07-01 |
| Dapagliflozin in Active Lupus Nephritis Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo - Lupus Nephritis (LN) | Phase 4 | Recruiting | Brigham and Women's Hospital | 33 | 2026-05-19 | 2026-05-26 |
| Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy CD19 CAR-γδ T cell - Membranous Nephropathy, Lupus Nephritis (LN) | Early Phase 1 | Not yet recruiting | Air Force Military Medical University, China | 15 | 2026-05-01 | 2026-04-16 |
| A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) HB2198 - Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | Hinge Bio | 30 | 2026-03-23 | 2026-03-25 |
| Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus CRC01 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Not yet recruiting | Curocell Inc. | 39 | 2026-02-01 | 2026-01-23 |
| Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis Vonsetamig, Odronextamab - Lupus Nephritis (LN) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2025-12-22 | 2026-10-27 |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
Showing 20 of 38. Sign in to see all of them.
Lupus Nephritis (38) · Lupus Erythematosus, Systemic (19) · Autoimmune Diseases (5) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Antiphospholipid Syndrome (3) · Myositis (3) · Glomerulonephritis, IGA (2) · Glomerulonephritis, Membranous (2) · Recurrence (2) · Arthritis, Rheumatoid (1) · Camurati-Engelmann Syndrome (1) · Complement Component 3 Deficiency, Autosomal Recessive (1) · Disease (1) · Immunoglobulin G4-Related Disease (1) · Kidney Failure, Chronic (1)
Connective Tissue Diseases (38) · Female Urogenital Diseases (38) · Female Urogenital Diseases and Pregnancy Complications (38) · Glomerulonephritis (38) · Immune System Diseases (38) · Kidney Diseases (38) · Male Urogenital Diseases (38) · Skin and Connective Tissue Diseases (38) · Urogenital Diseases (38) · Urologic Diseases (38) · Nephritis (37) · Autoimmune Diseases (33) · Lupus Erythematosus, Systemic (19) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6)
Tablets (3) · dapagliflozin (2) · Adrenal Cortex Hormones (1) · CTL019 chimeric antigen receptor (1) · Critical Pathways (1) · Glucocorticoids (1) · Mycophenolic Acid (1) · Prednisone (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · Standard of Care (1) · TACI receptor-IgG Fc fragment fusion protein (1) · belimumab (1) · empagliflozin (1) · telitacicept (1)
Assiut University (5) · China Immunotech (Beijing) Biotechnology Co., Ltd. (4) · AbelZeta Inc. (2) · Beijing GoBroad Hospital (2) · Ahmed Yehia Ismail (1) · Ain Shams University (1) · Air Force Military Medical University, China (1) · Akebia Therapeutics (1) · Brigham and Women's Hospital (1) · Children's Hospital of Philadelphia (1) · Curocell Inc. (1) · Duke University (1) · Federico II University (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Haisco Pharmaceutical Group Co., Ltd. (1)
China (14) · United States (10) · Egypt (4) · Spain (3) · Australia (1) · Brazil (1) · France (1) · Germany (1) · Mexico (1) · Puerto Rico (1) · South Korea (1) · Taiwan (1)
Alberto Ortiz Arduan (1) · Caitlin Elgarten, MD (1) · Hongmei Song, MD, PhD (1) · Huji Xu, Ph.D, MD (1) · Jing Pan, Ph.D (1) · Joanne Curley (1) · Joy N Buie, PhD, MSCR, RN (1) · Kai Sun, MD, MS (1) · Radwa Awad Abdelhafiz, PhD doctorate (1) · Samir Kamal (1) · Scott Antonia (1) · Scott Antonia, MD, PhD (1)
PMID 16881113, PMID 20414362, PMID 22566930, PMID 25031267, PMID 30009962, PMID 30177078, PMID 31779843, PMID 32500443, PMID 33280015, PMID 36774306, PMID 36864291, PMID 36864848, PMID 37989451, PMID 38180339, PMID 38182286, PMID 38661083, PMID 39511276
2025 (1)